Focused on developing novel oncology and endocrine therapies, this biopharmaceutical company specializes in treatments for rare diseases and unmet medical needs. Investors monitor its pipeline of clinical-stage assets, particularly in oncology, where it has several candidates in development.
1 member of Congress has disclosed 2 trades in Aeterna Zentaris Inc. (AEZS), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 1 sale. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2017-07-20 | Roger W. Marshall | sell | $1K – $15K |
| 2017-07-19 | Roger W. Marshall | buy | $1K – $15K |